The groundbreaking success of Sildenafil undeniably reshaped the medication landscape, but investing in companies primarily reliant on off-patent versions presents a challenging picture. While early profits were significant, the cessation of patents and the rise of discounted alternatives have diminished the customer base. Therefore, a thorough ass